Reversal of Paclitaxel Resistance in Epithelial Ovarian Carcinoma Cells by a MUC1 Aptamer-let-7i Chimera

Author： Liu Nenghui Zhou Changju Zhao Jingfeng Chen Yuxiang

ISSN： 0735-7907

Source： Cancer Investigation, Vol.30, Iss.8, 2012-10, pp. : 577-582

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Phase I Study of Weekly Topotecan and Paclitaxel in Previously Treated Epithelial Ovarian Carcinoma Patients

By Homesley H. Benigno B. Williams J. Vaccarello L.

Gynecologic Oncology, Vol. 87, Iss. 2, 2002-11 ,pp. : 171-177

Academic Press

Access to resources Recommend Favorite

Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: The prediction value of ERCC1 and Tau expression

International Journal of Oncology, Vol. 44, Iss. 5, 2014-01 ,pp. : 1736-1744

Spandidos Publications

Access to resources Recommend Favorite

Increased paclitaxel resistance in recurrent epithelial ovarian cancer: analysis of metachronous tumors

By Matsuo Koji Im Dwight Rosenshein Neil

International Journal of Clinical Oncology, Vol. 15, Iss. 3, 2010-06 ,pp. : 325-327

Springer Publishing Company

Access to resources Recommend Favorite

FSH stimulates expression of the embryonic gene HMGA2 by downregulating let-7 in normal fimbrial epithelial cells of ovarian high-grade serous carcinomas

Experimental and Therapeutic Medicine, Vol. 5, Iss. 1, 2013-01 ,pp. : 350-354

Spandidos Publications

Access to resources Recommend Favorite

Aflibercept in epithelial ovarian carcinoma

By Moroney John W Sood Anil K Coleman Robert L

Future Oncology, Vol. 5, Iss. 5, 2009-06 ,pp. : 591-600

Future Medicine

Access to resources Recommend Favorite